These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1815534)

  • 21. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
    Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
    Verstraete M; Su CA; Tanswell P; Feuerer W; Collen D
    Thromb Haemost; 1986 Aug; 56(1):1-5. PubMed ID: 3095944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
    Huber K; Beckmann R; Probst P; Rauscha F; Kaindl F; Binder BR
    Thromb Haemost; 1993 Jan; 69(1):45-9. PubMed ID: 8446938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation by HPLC of the catabolism of recombinant tissue plasminogen activator in the rat.
    Harris R; Frade LG; Creighton LJ; Gascoine PS; Alexandroni MM; Poole S; Gaffney PJ
    Thromb Haemost; 1988 Aug; 60(1):107-12. PubMed ID: 3142088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
    Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
    Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
    Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
    J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects.
    Tanswell P; Seifried E; Su PC; Feuerer W; Rijken DC
    Clin Pharmacol Ther; 1989 Aug; 46(2):155-62. PubMed ID: 2503283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens.
    Eppler S; Senn T; Gilkerson E; Modi NB
    Biopharm Drug Dispos; 1998 Jan; 19(1):31-8. PubMed ID: 9510983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.
    Tanswell P; Tebbe U; Neuhaus KL; Gläsle-Schwarz L; Wojcik J; Seifried E
    J Am Coll Cardiol; 1992 Apr; 19(5):1071-5. PubMed ID: 1372625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular catabolism of recombinant tissue-type plasminogen activator. Identification and characterization of a novel high affinity uptake system on rat hepatocytes.
    Bakhit C; Lewis D; Billings R; Malfroy B
    J Biol Chem; 1987 Jun; 262(18):8716-20. PubMed ID: 2439503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses.
    Bäumer W; Herrling GM; Feige K
    BMC Vet Res; 2013 Aug; 9():158. PubMed ID: 23938183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocytosis and intracellular processing of tissue-type plasminogen activator by rat liver cells in vivo.
    Stang E; Krause J; Seydel W; Berg T; Roos N
    Biochem J; 1992 Mar; 282 ( Pt 3)(Pt 3):841-51. PubMed ID: 1554369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microscopic clot fragment evidence of biochemo-mechanical degradation effects in thrombolysis.
    Bajd F; Vidmar J; Blinc A; Sersa I
    Thromb Res; 2010 Aug; 126(2):137-43. PubMed ID: 20580981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for carbohydrate-independent endocytosis of tissue-type plasminogen activator by liver cells.
    Stang E; Roos N; Schlüter M; Berg T; Krause J
    Biochem J; 1992 Aug; 285 ( Pt 3)(Pt 3):799-804. PubMed ID: 1323274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells.
    Kuiper J; Otter M; Rijken DC; van Berkel TJ
    J Biol Chem; 1988 Dec; 263(34):18220-4. PubMed ID: 3142872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.